NASH - NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NASH - NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NASH - NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NASH - NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial aims to halt progression of scarred livers
Disease control Recruiting nowThis large, late-stage study is testing whether a drug called efruxifermin can slow down or reverse liver damage in people who already have significant scarring (cirrhosis) from fatty liver disease (NASH/MASH). About 1,150 participants will receive either the drug or a placebo to…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New scan could replace painful liver biopsies for disease diagnosis
Diagnosis Recruiting nowThis study is testing a special type of MRI scan to see if it can accurately diagnose a serious liver condition called NASH (nonalcoholic steatohepatitis). Researchers want to see if this scan can identify patients who have both significant liver inflammation and scarring, which …
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Phase: NA • Sponsor: Perspectum • Aim: Diagnosis
Last updated Mar 30, 2026 14:33 UTC
-
Scientists probe hidden link between fat and liver damage
Knowledge-focused Recruiting nowThis study aims to understand how inflammation in body fat is connected to liver damage and insulin resistance in people with severe obesity. Researchers will examine tissue samples from 60 participants who are already scheduled for gastric bypass surgery. The goal is to gather k…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC